Category: Drug Safety Alerts
-
Glaxo’s Diabetes Drug Avandia May Cause Significant Heart Attack Risk
Avandia Might Have Prevented Diabetes In Some Patients, But Is This Benefit Offset By The Risk Of Heart Problems? (Posted by Tom Lamb at DrugInjuryWatch.com) On May 21, 2007 the Los Angeles Times published…
-
Natrecor Safety Controversy Considered In Two May 2007 Medical Journal Articles
Is Natrecor An Example Of Why Dr. Steven Nissen Thinks That The FDA Is Dysfunctional And In Need Of Reform? (Posted by Tom Lamb at DrugInjuryWatch.com) Natrecor (nesiritide) is approved for the treatment of…
-
Tysabri And PML: No New Reports Of Serious Brain Infection PML According To Biogen And Elan
Drug Companies Also State There Have Been No Reports Of Other "Serious Opportunistic Infections" Related To Recent Use Of Tysabri (Posted by Tom Lamb at DrugInjuryWatch.com) In a May 3, 2007 Wall Street Journal…
-
May 2007 FDA “Patient Safety News” Videos For Doctors Online
Covers Procrit, Aranesp & Epogen, As Well As Adderall, Ambien, And More (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA’s Patient Safety News (PSN) is a series of monthly video news shows intended primarily…
-
Significant Increase In Deaths For Aranesp Users In Comparison To Patients Taking Placebo
Amgen-Sponsored Study Was Testing Aranesp In Cancer Patients Who Developed Anemia (Posted by Tom Lamb at DrugInjuryWatch.com) An April 17, 2007 Wall Street Journal (WSJ) article about the results of a new study concerning…
-
FDA Orchestrates Voluntary Recall of Parkinson’s Disease Drug Permax
Action Follows News Of Studies Which Revealed Link To Serious Heart Valve Damage (Posted by Tom Lamb at DrugInjuryWatch.com) On March 29, 2007 the FDA announced that Permax as well as two generic pergolide…
-
Constipation Medication Zelnorm Linked To Apparent Increased Risk Of Heart Attacks And Strokes
Novartis Suspends Sales After FDA Determines That Risks Of Serious Side Effects Outweigh Benefits Of Zelnorm (Posted by Tom Lamb at DrugInjuryWatch.com) On March 30, 2007 the FDA announced that Novartis Pharmaceuticals Corporation had…
-
Heart Failure Drug Natrecor Fails Efficacy Part Of “Off-label” Use Study
Safety Profile Of Natrecor Continues To Be Subject Of Controversy And Debate (Posted by Tom Lamb at DrugInjuryWatch.com) The results of a large study for Johnson & Johnson’s heart failure drug Natrecor failed to…
-
Sanofi-Aventis Sends “Dear Doctor” Letter Regarding Antibiotic Ketek In Late March 2007
The Letter Concerns Black-Box Warning, Prescribing Changes, And Patient Medication Guide Announced Back In Mid-February 2007 (Posted by Tom Lamb at DrugInjuryWatch.com) On March 26, 2007 the FDA announced that a so-called "Dear Doctor"…
-
FDA Issues March 2007 Safety Alert For Pfizer Antibiotic Zyvox
Study Suggests That Higher Chance Of Death Is Related To The Type Of Organism Causing A Patient’s Infection (Posted by Tom Lamb at DrugInjuryWatch.com) On March 16, 2007 the FDA issued a safety alert…